Biochemistry and therapeutics of posthypoxic myoclonus.
Van Woert
M H
MH
Rosenbaum
D
D
Chung
E Y
EY
D006916:5-Hydroxytryptophan / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D001224:Aspartic Acid / Q000378:metabolism; D001569:Benzodiazepines / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D004569:Electroencephalography; D005998:Glycine / Q000378:metabolism; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D000860:Hypoxia / Q000150:complications*; D008784:Methysergide / Q000627:therapeutic use; D008954:Models, Biological; D009207:Myoclonus / Q000188:drug therapy* / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D012701:Serotonin / Q000378:metabolism; D014364:Tryptophan / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D001569:Benzodiazepines; D001224:Aspartic Acid; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D014364:Tryptophan; D000324:Adrenocorticotropic Hormone; D006916:5-Hydroxytryptophan; D002230:Carbidopa; D005998:Glycine; D011241:Prednisone; D008784:Methysergide